^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QN-023a
i
Other names: QN-023a
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Qihan Biotech
Drug class:
NK cell stimulant, CD33 inhibitor
Related drugs:
9d
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=3, Terminated, Institute of Hematology & Blood Diseases Hospital, China | N=18 --> 3 | Recruiting --> Terminated; It did not reach the expected results of clinical trial
Enrollment change • Trial termination
|
CD33 (CD33 Molecule)
|
CD33 positive
|
cytarabine • fludarabine IV • QN-023a
almost2years
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=19, Recruiting, Zhejiang University
New P1 trial
|
CD33 (CD33 Molecule)
|
CD33 positive
|
cytarabine • fludarabine IV • QN-023a
almost2years
Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia (ASH 2022)
Immune cell therapy has become a cornerstone in cancer therapy. When administered in combination with daratumumab, QN-023a demonstrated superior ADCC compared to unmodified iPSC-derived NK cells against primary AML blasts from patients. Together, we have engineered iPSC-derived QN-023a NK cells as promising clinical drug candidates for treatment of AML.
IO biomarker
|
CD33 (CD33 Molecule) • IL15 (Interleukin 15) • NKG2D (killer cell lectin like receptor K1)
|
Darzalex (daratumumab) • CD33 CAR-T • QN-023a
2years
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=18, Recruiting, Institute of Hematology & Blood Diseases Hospital
New P1 trial
|
CD33 (CD33 Molecule)
|
CD33 positive
|
cytarabine • fludarabine IV • QN-023a
Share via
